Fetomaternal outcomes of mothers with detectable cytomegalo virus (CMV)-specific IgM antibodies

Background: Human cytomegalovirus (CMV) infection is the most common cause of perinatal viral infection. congenital CMV infection can produce varying degrees of neurodevelopmental disabilities. Aims and objectives were to study the fetomaternal outcome in CMV-Specific IgM antibodies.Methods: The study was prospective for a period of one and a half year. Hundred high risk patients with hundred controls were screened for CMV serology IgM. Maternal & fetal outcomes were noted.Results: Out of 100 cases in study group 27(27%) were positive for CMV IgM while in control group 6(6%) were positive(p<0.05). Primary CMV infection in mothers led to abortion in 2(7.4%) patients, pre-term labour in 5(18.5%), Postpartum hemorrhage in 6 (22.2%), fetal distress in 11(40.7%) while 37% had uneventful outcome. Among CMV positive cases 48.1% were born term live, 6(22.2%) were preterm, 1(3.7%) had IUD, Intrauterine growth restriction in 10 (37%), 6(22.2%) with congenital defect and 4(14.8%) with neonatal manifestations.Conclusions: CMV remains a significant public health concern. Education of young women in our community regarding hygienic and behavioral approaches that can help prevent CMV transmission is mandatory

Open policy for wireless computers in classrooms: What makes it a good or a bad idea?

Increasingly, studies and media articles have been looking into possible adverse effects of open policies for using wireless ready computers in classrooms. Tablet PCs, as indicated by some of those authors, are under suspicion more than laptops because they make it harder for instructor to determine whether they are used productively or for off-the-task purposes. In this study students were invited to voluntarily bring their personal wireless computers to introductory physics classes in order to utilize them with DyKnow software. We compare performance of students who consistently used computers in classroom with those who did so less frequently or not at all. We also gauge how student attitudes and recommendations related to DyKnow software and Tablet PCs vary by the type of computer that was available to them in this course

Rapid synthesis of Tb3+-doped gadolinium oxyhydroxide and oxide green phosphors and their biological behaviour

Green phosphors based on terbium doped GdOOH and Gd2O3 powders are prepared through a rapid microwave-assisted solution based method using ethanol as a solvent and without using anysurfactants. The as-prepared Tb3+:GdOOH powders are crystalline and show a flower-like morphology comprising many two-dimensional flake-like structures. The as-prepared powders show good luminescence properties under UV excitation and their conversion to Tb3+:Gd2O3 by annealing takes place at modest temperatures. A considerable increase in luminescence intensity is observed for the annealed powders, which is ascribed to phase change from oxyhydroxide to oxide as well as an increase in crystallinity as a result of annealing. Cytotoxicity studies reveal that the as-prepared powders show considerable toxicity towards the cells, whereas the annealed powders do not hamper the cell growth.

LENGTH-WEIGHT RELATIONSHIP AND CONDITION FACTOR OF SEVEN FISH SPECIES IN MANASBAL LAKE, KASHMIR, INDIA

Za procjenu akvakulture, dužinsko-maseni odnos i faktor kondicije smatraju se standardnim metodama za određivanje rasta ribe, njihova zdravlja i potencijalnog prinosa. Jednogodišnje istraživanje je provedeno radi izračunavanja dužinsko-masenih odnosa (LWRs) i faktora kondicije (K) za sedam ribljih vrsta, Schizothorax niger, S. curvifrons, Cyprinus carpio, Carassius carassius, Pethia conchonius, Crossocheilus diplochilus i Gambusia holbrooki u jezeru Manasbal. Rezultatima je utvrđeno da četiri ulovljene vrste riba (S. niger, S. curvifrons, C. diplochilus i G. holbrooki) pokazuju negativan alometrijski rast, dok su druge vrste riba (C. carpio, C. carassius, P. conchonius) pokazale pozitivan alometrijski rast. LWR je bio značajan pri P < 0,01 u svih sedam vrsta riba, s koeficijentom determinacije (R2) u rasponu između 0,73 i 0,96. K je bio viši kod C. carpio nego kod C. carassius, P. conchonius, G. holbrooki, C. diplochilus, S. niger i S. curvifrons. Trenutna studija koja daje LWR i faktor kondicije sedam vrsta riba iz jezera Manasbal, Kašmir bit će korisna za upravljanje ribljim vrstama, kao i za procjenu ekološkog stanja jezera.For aquaculture assessments, the length-weight relationship and condition factor are considered standard methods for determining fish growth, its health and the potential yield. A year-long study was conducted to calculate length-weight relationships (LWRs) and condition factor (K) for seven fish species, Schizothorax niger (Alghad snowtrout), S. curvifrons (Sattar snowtrout), Cyprinus carpio (Common carp), Carassius carassius (Crucian carp), Pethia conchonius (Rosy barb), Crossocheilus diplochilus (Kashmir latia) and Gambusia holbrooki (Mosquito fish) in Manasbal Lake. The results revealed that four captured fish species (S. niger, S. curvifrons, C. diplochilus and G. holbrooki) exhibited negative allometric growth, while other fish species (C. carpio, C. carassius, P. conchonius) exhibited positive allometric growth. LWR was significant at P < 0.01 in all seven fish species, with a coefficient of determination (R2) ranging between 0.73 to 0.96. The K was higher in C. carpio than C. carassius, P. conchonius, G. holbrooki, C. diplochilus, S. niger and S. curvifrons. The current study providing the LWRs and condition factor of seven fish species from Manasbal Lake, Kashmir will be helpful for the management of fish species as well as for assessing the ecological condition of the Lake

Two stage flexor tendon reconstruction in hand: our experience

Background: Flexor tendon injuries in the digital flexor sheath area (zone II) are the most difficult to treat and remain a focus of both clinical attention and basic investigations. This prospective study was designed to evaluate the results of staged zone II flexor tendon repair.Methods: Seventy digits in thirty five patients were treated by Two Stage flexor tendon reconstruction and followed for an average of one and a half year. The procedure included placing a silicone catheter (cut to desire size) as an active implant and reconstruction of A2, A4 or both pulleys if damaged in first stage. During the second stage (performed three to eight months later), tendon graft replaced the silicone catheter in the pseudo sheath formed around the catheter. The proximal end of the transplanted tendon was fixed with flexor digitorum profundus tendon of respective finger using the Pulvertaft method, and the distal end of the graft was fixedwith the distal stump of respective flexor digitorum profundus tendon. Early controlled motion protocol was instituted in all cases.Results: As per Buck Gramcko scale total active motion obtained was Excellent in 70%, Good in 20%, Fair in 7.1%, and Poor in 2.9% of patients.Conclusions: Flexor tendon reconstruction using two stage tendon reconstructions is an effective way to restore digital tendon function in delayed zone II flexor tendon injuries

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

Prevalence of acute viral hepatitis in women presenting with jaundice with fetomaternal outcome

The present study aimed to find out prevalence of acute viral hepatitis in women presenting with jaundice with fetomaternal outcome in LallaDed hospital, which is a tertiary care hospital in Srinagar, J&K, India The study was conducted in 80 consecutive pregnant patients presenting with jaundice. Patients were evaluated on basis of history, examination, liver function profile and serological markers for A, B, C&E viruses. Viral hepatitis was cause of jaundice in 70% of cases with HEV accounting for 45% of cases and HBV accounting for 25% of cases. Abortion, IUGR, preterm labor, PPH was common complications in patients with HbsAg positivity. In HEV IgM positive women prematurity (33%) was most common complication. 4(11%) maternal deaths occurred in women positive for HEV IgM. Viral hepatitis was predominant cause of jaundice with HEV causing majority of cases. Prematurity was common complication of HEV. Maternal mortality was 11% in HEV positive cases